Lytix, Pharmasum Therapeutics neurology news

Infectious disease and cancer company Lytix spun out Pharmasum to develop PST-900, a dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitor to treat dementia. Pharmasum hopes to move the discovery-stage compound into the clinic in 2016. Pharmasum will be led by CEO Anders Fugelli and CSO John Svendsen. Fugelli was Lytix's head of business development and commercialization, and Svendsen was head of exploratory research. The company is looking to raise £2 million ($3.3 million). ...